Go Pro
→ The case for $20,000 gold before year end (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MannKind Corporation stock logo
MNKD
MannKind
$3.34
-0.1%		$3.86
$2.23
▼
$6.51
$1.07B1.15.20 million shs126,885 shs
ODTX
Odyssey Therapeutics
$21.94
-2.2%		$22.57
$15.10
▼
$29.05
$1.05BN/A302,348 shs34,234 shs
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$9.55
+0.2%		$13.68
$1.90
▼
$23.57
$280.31M0.21738,910 shs1.55 million shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$19.25
+5.0%		$22.12
$6.50
▼
$49.64
$1.15B1.711.07 million shs115,206 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MannKind Corporation stock logo
MNKD
MannKind
-0.30%-4.30%-15.44%-17.53%-38.03%
ODTX
Odyssey Therapeutics
+4.52%-3.86%-7.88%+35.10%+2,243,999,900.00%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
+3.25%-9.84%-36.59%-24.37%+391.24%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
+0.11%-16.68%-19.07%-0.33%-54.05%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MannKind Corporation stock logo
MNKD
MannKind
$3.34
-0.1%		$3.86
$2.23
▼
$6.51
$1.07B1.15.20 million shs126,885 shs
ODTX
Odyssey Therapeutics
$21.94
-2.2%		$22.57
$15.10
▼
$29.05
$1.05BN/A302,348 shs34,234 shs
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$9.55
+0.2%		$13.68
$1.90
▼
$23.57
$280.31M0.21738,910 shs1.55 million shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$19.25
+5.0%		$22.12
$6.50
▼
$49.64
$1.15B1.711.07 million shs115,206 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MannKind Corporation stock logo
MNKD
MannKind
-0.30%-4.30%-15.44%-17.53%-38.03%
ODTX
Odyssey Therapeutics
+4.52%-3.86%-7.88%+35.10%+2,243,999,900.00%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
+3.25%-9.84%-36.59%-24.37%+391.24%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
+0.11%-16.68%-19.07%-0.33%-54.05%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
MannKind Corporation stock logo
MNKD
MannKind
2.50
Moderate Buy$8.34149.81% Upside
ODTX
Odyssey Therapeutics
2.63
Moderate Buy$35.7559.31% Upside
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
2.88
Moderate Buy$30.60221.09% Upside
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.90
Moderate Buy$41.71127.57% Upside

Current Analyst Ratings Breakdown

Latest QTTB, VOR, ODTX, and MNKD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/28/2026
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$29.00
9/28/2026
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$29.00
9/16/2026
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/14/2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C-)
9/11/2026
MannKind Corporation stock logo
MNKD
MannKind
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$8.00
9/7/2026
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/3/2026
MannKind Corporation stock logo
MNKD
MannKind
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
8/27/2026
ODTX
Odyssey Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$44.00
8/27/2026
ODTX
Odyssey Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$44.00
8/24/2026
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$34.00
8/21/2026
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
(Data available from 9/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
MannKind Corporation stock logo
MNKD
MannKind
$348.97M3.08$0.06 per share54.14($0.17) per share-19.65
ODTX
Odyssey Therapeutics
$99K10,893.37N/AN/AN/A∞
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$53.74M5.28$1.56 per share6.09$3.41 per share2.79
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
MannKind Corporation stock logo
MNKD
MannKind
$5.86M-$0.13N/AN/AN/A-11.08%-11.21%-6.31%11/4/2026 (Estimated)
ODTX
Odyssey Therapeutics
N/A-$6.77N/AN/AN/AN/AN/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$29.82M$3.003.18N/AN/AN/A50.17%29.49%11/12/2026 (Estimated)
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest QTTB, VOR, ODTX, and MNKD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-$0.69-$0.80-$0.11-$1.16N/AN/A
8/5/2026Q2 2026
MannKind Corporation stock logo
MNKD
MannKind
-$0.0075-$0.01-$0.0025-$0.06$108.08 million$109.37 million
8/5/2026Q2 2026
ODTX
Odyssey Therapeutics
N/A-$1.74N/A-$1.74N/AN/A
8/5/2026Q2 2026
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$0.46-$0.44+$0.02-$0.44$0.75 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
MannKind Corporation stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A
ODTX
Odyssey Therapeutics
N/AN/AN/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
N/AN/AN/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
MannKind Corporation stock logo
MNKD
MannKind
N/A
1.72
1.41
ODTX
Odyssey Therapeutics
N/A
11.36
11.36
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
N/A
20.30
20.30
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
MannKind Corporation stock logo
MNKD
MannKind
49.55%
ODTX
Odyssey Therapeutics
N/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
31.32%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
97.29%

Insider Ownership

CompanyInsider Ownership
MannKind Corporation stock logo
MNKD
MannKind
2.60%
ODTX
Odyssey Therapeutics
N/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
34.46%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
0.27%
CompanyEmployeesShares OutstandingFree FloatOptionable
MannKind Corporation stock logo
MNKD
MannKind
592321.54 million313.18 millionOptionable
ODTX
Odyssey Therapeutics
10048.06 millionN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
2229.77 million19.51 millionN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
7659.16 million59.00 millionN/A

Recent News About These Companies

Vor Biopharma: Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
September 29 at 7:33 PM  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69706309-vor-biopharma-telitacicept-demonstrates-deep-and-durable-minimal-symptom-expression-through-48-weeks-in-generalized-myasthenia-gravis-399.htm
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
September 29 at 12:59 PM  |  marketscreener.comM
Vor Biopharma en hausse après la publication de résultats encourageants concernant un médicament contre les maladies auto-immunes
September 29 at 12:59 PM  |  boursorama.comB
Telitacicept Demonstrates Deep and Durable Minimal Symptom  Expression Through 48 Weeks in Generalized Myasthenia Gravis
September 29 at 8:05 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3370807/0/en/telitacicept-demonstrates-deep-and-durable-minimal-symptom-expression-through-48-weeks-in-generalized-myasthenia-gravis.html
Vor Biopharma (VOR) Gets a Buy from Stifel Nicolaus
September 29 at 7:59 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VOR/pressreleases/4850802/vor-biopharma-vor-gets-a-buy-from-stifel-nicolaus/
Vor Biopharma Inc. (NASDAQ:VOR) Stock Rated "Moderate Buy" by Sell-Side Brokerages
September 28 at 2:44 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31056562
Vor Biopharma Inc. (NASDAQ:VOR) Stock Has Average Price Target of $41.71 According to Brokerages
September 28 at 2:43 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-vor-biopharma-inc-nasdaq-vor-stock-has-average-price-target-of-4171-according-to-brokerages-2026-09-28/
【VOR】Vor Biopharma
September 23, 2026  |  note.comN
Vor Biopharma no fórum Stifel 2026: telitacicept aposta em dupla estratégia
September 23, 2026  |  br.investing.comhttps://br.investing.com/news/transcripts/vor-biopharma-no-forum-stifel-2026-telitacicept-aposta-em-dupla-estrategia-93CH-2073344
Vor Biopharma在Stifel 2026论坛上阐述telitacicept双路径布局
September 23, 2026  |  cn.investing.comhttps://cn.investing.com/news/transcripts/article-93CH-3580464
Vor Biopharma al forum Stifel 2026: telitacicept punta su doppia strategia
September 23, 2026  |  it.investing.comhttps://it.investing.com/news/transcripts/vor-biopharma-al-forum-stifel-2026-telitacicept-punta-su-doppia-strategia-93CH-3560029
Vor Biopharma en foro Stifel 2026: telitacicept avanza en doble vía
September 23, 2026  |  mx.investing.comhttps://mx.investing.com/news/transcripts/vor-biopharma-en-foro-stifel-2026-telitacicept-avanza-en-doble-via-93CH-3774116
Vor Biopharma (NASDAQ:VOR) Shares Down 8.2% - Should You Sell?
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vor-biopharma-nasdaq-vor-shares-down-82-should-you-sell-2026-09-23/
Vor Biopharma (NASDAQ:VOR) Trading Up 6.1% - Still a Buy?
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vor-biopharma-nasdaq-vor-trading-up-61-still-a-buy-2026-09-22/
Vor Biopharma: A Funded Replication Story With Franchise Potential
September 18, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4947759-vor-biopharma-a-funded-replication-story-with-franchise-potential
Vor Biopharma Inc. (VOR) Stock Price, News, Quote & History - Yahoo Finance
September 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/VOR/latest-news/
Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
September 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4944756-vor-biopharma-inc-vor-presents-at-citigroups-biopharma-back-to-school-summit-2026-transcript
Vor Biopharma (NASDAQ:VOR) Stock Price Down 5.4% - Should You Sell?
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vor-biopharma-nasdaq-vor-stock-price-down-54-should-you-sell-2026-09-09/
97,722 Shares in Vor Biopharma Inc. $VOR Purchased by Bank of New York Mellon Corp
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-97722-shares-in-vor-biopharma-inc-vor-purchased-by-bank-of-new-york-mellon-corp-2026-09-09/
Vor Biopharma Completes Enrollment in Phase 3 Trial of Investigational Drug for Generalized Myasthenia Gravis
September 8, 2026  |  marketscreener.comM
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357492/0/en/vor-completes-enrollment-of-global-phase-3-upstream-mg-trial-and-expands-telitacicept-global-franchise-into-ocular-myasthenia-gravis.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Scientist handles blood sample in lab, symbolizing early cancer detection.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
By Bridget Bennett | September 6, 2026
Split image showing a GameStop store checkout counter beside a laptop displaying the eBay website, with a graded Pokémon card nearby.
GameStop’s Comeback Case Is Getting Interesting, But eBay Still Looks Stronger
By Thomas Hughes | September 10, 2026
Dell logo illuminated in a data center setting with a laptop and server racks visible nearby.
One of Trump's Favorite Stocks Just Reported Blowout Earnings
By Jessica Mitacek | September 3, 2026
A fighter jet with open engine panels sits on an aircraft carrier deck at sunset, with the ship's superstructure visible in the background.
Defense Stocks Are Pulling Back as Their Navy Tailwinds Get Stronger
By Jeffrey Neal Johnson | September 4, 2026
A hard disk drive stands upright on a server rack in a data center aisle lined with illuminated equipment.
5 Buy-and-Hold Stocks Built to Weather a Volatile Market
By Chris Markoch | September 16, 2026
MannKind stock logo

MannKind NASDAQ:MNKD

$3.34 -0.01 (-0.15%)
As of 10:20 AM Eastern
This is a fair market value price provided by Massive. Learn more.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Odyssey Therapeutics NASDAQ:ODTX

$21.94 -0.50 (-2.23%)
As of 10:03 AM Eastern

Odyssey Therapeutics Inc. is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc. is based in BOSTON.

Q32 Bio stock logo

Q32 Bio NASDAQ:QTTB

$9.55 +0.02 (+0.20%)
As of 10:20 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Vor Biopharma stock logo

Vor Biopharma NASDAQ:VOR

$19.25 +0.92 (+5.02%)
As of 10:20 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas